BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yang MW, Fu XL, Jiang YS, Chen XJ, Tao LY, Yang JY, Huo YM, Liu W, Zhang JF, Liu PF, Liu Q, Hua R, Zhang ZG, Sun YW, Liu DJ. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. World J Gastroenterol 2019; 25(14): 1684-1696 [PMID: 31011254 DOI: 10.3748/wjg.v25.i14.1684]
URL: https://www.wjgnet.com/1007-9327/full/v25/i14/1684.htm
Number Citing Articles
1
Guanghui Xu, Yuhao Wang, Hushan Zhang, Xueke She, Jianjun Yang. Immunotherapy and potential predictive biomarkers in the treatment of neuroendocrine neoplasiaFuture Oncology 2021; 17(9): 1069 doi: 10.2217/fon-2020-0703
2
Mengyuan Liu, Elizabeta C. Popa, Brendan M. Finnerty, Thomas J. Fahey, Rasa Zarnegar. Clinicopathological Features of Gastroesophageal Neuroendocrine NeoplasmsCurrent Gastroenterology Reports 2020; 22(10) doi: 10.1007/s11894-020-00788-w
3
Caroline Lum, Sophia Frentzas. Research and Clinical Applications of Targeting Gastric Neoplasms2021; : 317 doi: 10.1016/B978-0-323-85563-1.00010-1
4
Chunyan Hu, Shu Tian, Lan Lin, Jiahao Zhang, Hao Ding. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinomaOral Oncology 2020; 102: 104560 doi: 10.1016/j.oraloncology.2019.104560
5
Alexander W. MacFarlane, Ho-Man Yeung, R. Katherine Alpaugh, Essel Dulaimi, Paul F. Engstrom, Arvind Dasari, Kerry S. Campbell, Namrata Vijayvergia. Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasmsCancer Immunology, Immunotherapy 2021; 70(7): 1893 doi: 10.1007/s00262-020-02811-5
6
Z. Liu, F. Mi, M. Han, M. Tian, L. Deng, N. Meng, J. Luo, R. Fu. Bone marrow‐derived mesenchymal stem cells inhibit CD8 + T cell immune responses via PD‐1/PD‐L1 pathway in multiple myeloma Clinical & Experimental Immunology 2021; 205(1): 53 doi: 10.1111/cei.13594
7
Wei Liu, Lei Zhang, Zhiming Xiu, Jian Guo, Liye Wang, Yue Zhou, Yang Jiao, Meiyan Sun, Jianhui Cai. <p>Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer</p>OncoTargets and Therapy 2020; : 7229 doi: 10.2147/OTT.S255491
8
Anja Rinke, Christoph J Auernhammer, Lisa Bodei, Mark Kidd, Sebastian Krug, Rita Lawlor, Ilaria Marinoni, Aurel Perren, Aldo Scarpa, Halfdan Sorbye, Marianne Ellen Pavel, Matthias M Weber, Irvin Modlin, Thomas M Gress. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?Gut 2021; 70(9): 1768 doi: 10.1136/gutjnl-2020-321300
9
Jiazhang Xing, Hongyan Ying, Ji Li, Yang Gao, Zhao Sun, Jiarui Li, Chunmei Bai, Yuejuan Cheng, Huanwen Wu. Immune Checkpoint Markers in Neuroendocrine Carcinoma of the Digestive SystemFrontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.00132
10
Ilaria Maggio, Lisa Manuzzi, Giuseppe Lamberti, Angela Dalia Ricci, Nastassja Tober, Davide Campana. Landscape and Future Perspectives of Immunotherapy in Neuroendocrine NeoplasiaCancers 2020; 12(4): 832 doi: 10.3390/cancers12040832
11
Satoshi Yamashita, Hiroyuki Abe, Akiko Kunita, Hiroharu Yamashita, Yasuyuki Seto, Tetsuo Ushiku. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinomaHistopathology 2021; 78(3): 381 doi: 10.1111/his.14230
12
Virginia Corbett, Susanne Arnold, Lowell Anthony, Aman Chauhan. Management of Large Cell Neuroendocrine CarcinomaFrontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.653162